199 results on '"Honarpour, Narimon"'
Search Results
2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
- Author
-
Sabatine, Marc S, Giugliano, Robert P, Keech, Anthony C, Honarpour, Narimon, Wiviott, Stephen D, Murphy, Sabina A, Kuder, Julia F, Wang, Huei, Liu, Thomas, Wasserman, Scott M, Sever, Peter S, Pedersen, Terje R, and FOURIER Steering Committee and Investigators
- Subjects
FOURIER Steering Committee and Investigators ,Humans ,Cardiovascular Diseases ,Hypercholesterolemia ,Antibodies ,Monoclonal ,Anticholesteremic Agents ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Drug Therapy ,Combination ,Incidence ,Least-Squares Analysis ,Follow-Up Studies ,Double-Blind Method ,Aged ,Middle Aged ,Female ,Male ,Atherosclerosis ,Cholesterol ,LDL ,Antibodies ,Monoclonal ,Humanized ,Proprotein Convertase 9 ,Cardiovascular ,Clinical Research ,Heart Disease - Coronary Heart Disease ,Heart Disease ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,General & Internal Medicine ,Medical and Health Sciences - Abstract
BackgroundEvolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.MethodsWe conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years.ResultsAt 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P
- Published
- 2017
3. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF
- Author
-
Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Legg, Jason C., Büchele, Gustavo, Varin, Claire, Kurtz, Christopher E., Malik, Fady I., and Honarpour, Narimon
- Published
- 2020
- Full Text
- View/download PDF
4. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
- Author
-
Helgason, Hannes, primary, Eiriksdottir, Thjodbjorg, additional, Ulfarsson, Magnus O., additional, Choudhary, Abhishek, additional, Lund, Sigrun H., additional, Ivarsdottir, Erna V., additional, Hjorleifsson Eldjarn, Grimur, additional, Einarsson, Gudmundur, additional, Ferkingstad, Egil, additional, Moore, Kristjan H. S., additional, Honarpour, Narimon, additional, Liu, Thomas, additional, Wang, Huei, additional, Hucko, Thomas, additional, Sabatine, Marc S., additional, Morrow, David A., additional, Giugliano, Robert P., additional, Ostrowski, Sisse Rye, additional, Pedersen, Ole Birger, additional, Bundgaard, Henning, additional, Erikstrup, Christian, additional, Arnar, David O., additional, Thorgeirsson, Gudmundur, additional, Masson, Gísli, additional, Magnusson, Olafur Th., additional, Saemundsdottir, Jona, additional, Gretarsdottir, Solveig, additional, Steinthorsdottir, Valgerdur, additional, Thorleifsson, Gudmar, additional, Helgadottir, Anna, additional, Sulem, Patrick, additional, Thorsteinsdottir, Unnur, additional, Holm, Hilma, additional, Gudbjartsson, Daniel, additional, and Stefansson, Kari, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
- Author
-
Parikh, Kishan S., Sharma, Kavita, Fiuzat, Mona, Surks, Howard K., George, Jyothis T., Honarpour, Narimon, Depre, Christopher, Desvigne-Nickens, Patrice, Nkulikiyinka, Richard, Lewis, Gregory D., Gomberg-Maitland, Mardi, O’Connor, Christopher M., Stockbridge, Norman, Califf, Robert M., Konstam, Marvin A., Januzzi, James L., Jr., Solomon, Scott D., Borlaug, Barry A., Shah, Sanjiv J., Redfield, Margaret M., and Felker, G. Michael
- Published
- 2018
- Full Text
- View/download PDF
6. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- Author
-
Sabatine, Marc S, Leiter, Lawrence A, Wiviott, Stephen D, Giugliano, Robert P, Deedwania, Prakash, De Ferrari, Gaetano M, Murphy, Sabina A, Kuder, Julia F, Gouni-Berthold, Ioanna, Lewis, Basil S, Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, and Pedersen, Terje R
- Published
- 2017
- Full Text
- View/download PDF
7. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
- Author
-
Raal, Frederick J, Hovingh, G Kees, Blom, Dirk, Santos, Raul D, Harada-Shiba, Mariko, Bruckert, Eric, Couture, Patrick, Soran, Handrean, Watts, Gerald F, Kurtz, Christopher, Honarpour, Narimon, Tang, Lihua, Kasichayanula, Sree, Wasserman, Scott M, and Stein, Evan A
- Published
- 2017
- Full Text
- View/download PDF
8. Apaf-1 Deficiency and Neural Tube Closure Defects are Found in fog Mice
- Author
-
Honarpour, Narimon, Gilbert, Sandra L., Lahn, Bruce T., Wang, Xiaodong, and Herz, Joachim
- Published
- 2001
9. Quantitative Microsphere System Omecamtiv Mecarbil Immunoassay and Omecamtiv Mecarbil Codevelopment
- Author
-
Go, Ning Fei, primary, Honarpour, Narimon, additional, and Rigl, Ted, additional
- Published
- 2019
- Full Text
- View/download PDF
10. List of Contributors
- Author
-
Alturkistani, Abrar, primary, An, Juanjuan, additional, Benda, Norbert, additional, Bienfait, Karina, additional, Blackler, Adele R., additional, Bøgsted, Martin, additional, Brindley, David, additional, Broich, Karl, additional, Brøndum, Rasmus F., additional, Brunhoeber, Patrick, additional, Bureau, Matthew, additional, Car, Josip, additional, Carter, Alison, additional, Clarke, Tara, additional, Clements, June, additional, Cross, Darren, additional, Doble, Brett, additional, Dolled-Filhart, Marisa, additional, Domazetoski, Elena, additional, Duncan, Mark W., additional, ElGabry, Ehab A., additional, Ellison, Aaron R., additional, Emancipator, Kenneth, additional, Enzmann, Harald, additional, Farooq, Maria, additional, Feng, Janine, additional, Foley, Kimberley, additional, Generalov, Evgenii, additional, Go, Ning Fei, additional, Goltsov, Alexey, additional, Green, George A., additional, Hersom, Maria, additional, Honarpour, Narimon, additional, Iddamalgoda, Lahiru, additional, Ikeda, Masayuki, additional, Jenkins, Suzanne, additional, Jørgensen, Jan Trøst, additional, Kapadia, Monesh, additional, Karwowska, Sylwia, additional, Kuzulugil, Sebnem S., additional, Lam, Ching, additional, Lewis, Jason S., additional, Li, Jinbo, additional, Liesenfeld, Oliver, additional, Lopes, Gilberto, additional, Luo, Dee, additional, Meinert, Edward, additional, Meyer, Ralf, additional, Mistry, Amita, additional, Mitsakakis, Nicholas, additional, Mollerup, Jens, additional, Montalto, Michael C., additional, Murata, Lauren B., additional, Murtaza, Muhammed, additional, Nielsen, Karsten Bork, additional, Pant, Saumya, additional, Parker, Jayson L., additional, Pereira, Patrícia M.R., additional, Ramarao, Manjunath, additional, Rigl, Ted, additional, Schildgen, Oliver, additional, Schildgen, Verena, additional, Scholl, Catharina, additional, Scudder, Sidney A., additional, Seyfried, Donna, additional, Sharma, Abha, additional, Shimazawa, Rumiko, additional, Simon, Richard, additional, Singh, Shalini, additional, Sobol, Nicholas B., additional, Stanforth, David A., additional, Stingl, Julia, additional, Sundararajan, Vijayaraghava Seshadri, additional, Suravajhala, Prashanth, additional, Tosolini, Alessandra, additional, Tsou, Jeff, additional, Tully, Kathryn M., additional, Walk, Eric E., additional, Wu, Dianna, additional, Xu, Xiaolei, additional, and Yu, Karen, additional
- Published
- 2019
- Full Text
- View/download PDF
11. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
- Author
-
Giugliano, Robert P., Pedersen, Terje R., Saver, Jeffrey L., Sever, Peter S., Keech, Anthony C., Bohula, Erin A., Murphy, Sabina A., Wasserman, Scott M., Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, and Sabatine, Marc S.
- Published
- 2020
- Full Text
- View/download PDF
12. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
- Author
-
Teerlink, John R, Felker, G Michael, McMurray, John J V, Solomon, Scott D, Adams, Kirkwood F, Jr, Cleland, John G F, Ezekowitz, Justin A, Goudev, Assen, Macdonald, Peter, Metra, Marco, Mitrovic, Veselin, Ponikowski, Piotr, Serpytis, Pranas, Spinar, Jindrich, Tomcsányi, János, Vandekerckhove, Hans J, Voors, Adriaan A, Monsalvo, Maria Laura, Johnston, James, Malik, Fady I, and Honarpour, Narimon
- Published
- 2016
- Full Text
- View/download PDF
13. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
- Author
-
Helgason, Hannes, Eiriksdottir, Thjodbjorg, Ulfarsson, Magnus O., Choudhary, Abhishek, Lund, Sigrun H., Ivarsdottir, Erna V., Hjorleifsson Eldjarn, Grimur, Einarsson, Gudmundur, Ferkingstad, Egil, Moore, Kristjan H.S., Honarpour, Narimon, Liu, Thomas, Wang, Huei, Hucko, Thomas, Sabatine, Marc S., Morrow, David A., Giugliano, Robert P., Ostrowski, Sisse Rye, Pedersen, Ole Birger, Bundgaard, Henning, Erikstrup, Christian, Arnar, David O., Thorgeirsson, Gudmundur, Masson, Gísli, Magnusson, Olafur Th, Saemundsdottir, Jona, Gretarsdottir, Solveig, Steinthorsdottir, Valgerdur, Thorleifsson, Gudmar, Helgadottir, Anna, Sulem, Patrick, Thorsteinsdottir, Unnur, Holm, Hilma, Gudbjartsson, Daniel, Stefansson, Kari, Helgason, Hannes, Eiriksdottir, Thjodbjorg, Ulfarsson, Magnus O., Choudhary, Abhishek, Lund, Sigrun H., Ivarsdottir, Erna V., Hjorleifsson Eldjarn, Grimur, Einarsson, Gudmundur, Ferkingstad, Egil, Moore, Kristjan H.S., Honarpour, Narimon, Liu, Thomas, Wang, Huei, Hucko, Thomas, Sabatine, Marc S., Morrow, David A., Giugliano, Robert P., Ostrowski, Sisse Rye, Pedersen, Ole Birger, Bundgaard, Henning, Erikstrup, Christian, Arnar, David O., Thorgeirsson, Gudmundur, Masson, Gísli, Magnusson, Olafur Th, Saemundsdottir, Jona, Gretarsdottir, Solveig, Steinthorsdottir, Valgerdur, Thorleifsson, Gudmar, Helgadottir, Anna, Sulem, Patrick, Thorsteinsdottir, Unnur, Holm, Hilma, Gudbjartsson, Daniel, and Stefansson, Kari
- Abstract
Importance: Whether protein risk scores derived from a single plasma sample could be useful for risk assessment for atherosclerotic cardiovascular disease (ASCVD), in conjunction with clinical risk factors and polygenic risk scores, is uncertain. Objective: To develop protein risk scores for ASCVD risk prediction and compare them to clinical risk factors and polygenic risk scores in primary and secondary event populations. Design, Setting, and Participants: The primary analysis was a retrospective study of primary events among 13540 individuals in Iceland (aged 40-75 years) with proteomics data and no history of major ASCVD events at recruitment (study duration, August 23, 2000 until October 26, 2006; follow-up through 2018). We also analyzed a secondary event population from a randomized, double-blind lipid-lowering clinical trial (2013-2016), consisting of individuals with stable ASCVD receiving statin therapy and for whom proteomic data were available for 6791 individuals. Exposures: Protein risk scores (based on 4963 plasma protein levels and developed in a training set in the primary event population); polygenic risk scores for coronary artery disease and stroke; and clinical risk factors that included age, sex, statin use, hypertension treatment, type 2 diabetes, body mass index, and smoking status at the time of plasma sampling. Main Outcomes and Measures: Outcomes were composites of myocardial infarction, stroke, and coronary heart disease death or cardiovascular death. Performance was evaluated using Cox survival models and measures of discrimination and reclassification that accounted for the competing risk of non-ASCVD death. Results: In the primary event population test set (4018 individuals [59.0% women]; 465 events; median follow-up, 15.8 years), the protein risk score had a hazard ratio (HR) of 1.93 per SD (95% CI, 1.75 to 2.13). Addition of protein risk score and polygenic risk scores significantly increased the C index when added to a clinical ri
- Published
- 2023
14. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
- Author
-
Kiyosue, Arihiro, Honarpour, Narimon, Kurtz, Christopher, Xue, Allen, Wasserman, Scott M., and Hirayama, Atsushi
- Published
- 2016
- Full Text
- View/download PDF
15. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- Author
-
Raal, Frederick J, Honarpour, Narimon, Blom, Dirk J, Hovingh, G Kees, Xu, Feng, Scott, Rob, Wasserman, Scott M, and Stein, Evan A
- Published
- 2015
- Full Text
- View/download PDF
16. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
- Author
-
Sabatine, Marc S., De Ferrari, Gaetano M., Giugliano, Robert P., Huber, Kurt, Lewis, Basil S., Ferreira, Jorge, Kuder, Julia F., Murphy, Sabina A., Wiviott, Stephen D., Kurtz, Christopher E., Honarpour, Narimon, Keech, Anthony C., Sever, Peter S., and Pedersen, Terje R.
- Published
- 2018
- Full Text
- View/download PDF
17. Inflammatory and Cholesterol Risk in the FOURIER Trial
- Author
-
Bohula, Erin A., Giugliano, Robert P., Leiter, Lawrence A., Verma, Subodh, Park, Jeong-Gun, Sever, Peter S., Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A., Keech, Anthony, Pedersen, Terje R., and Sabatine, Marc S.
- Published
- 2018
- Full Text
- View/download PDF
18. Abstract 16714: Characterization of Types and Sizes of Myocardial Infarction Reduced With Evolocumab in FOURIER
- Author
-
Wiviott, Stephen D, Giugliano, Robert P, Morrow, David A, De Ferrari, Gaetano M, Lewis, Basil S, Huber, Kurt, Kuder, Julia F, Murphy, Sabina A, Forni, Danielle M, Kurtz, Christopher, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R, and Sabatine, Marc S
- Published
- 2017
19. Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial
- Author
-
Murphy, Sabina A, Pedersen, Terje R, Gaciong, Zbigniew A, Ceska, Richard, Ezhov, Marat V, Connolly, Derek, Kraydashenko, Oleg, Jukema, J. Wouter, Toth, Kalman, Tikkanen, Matti J, Im, Kyungah, Wiviott, Stephen D, Kurtz, Christopher, Honarpour, Narimon, Giugliano, Robert P, Keech, Anthony C, Sever, Peter S, and Sabatine, Marc S
- Published
- 2017
20. CARDIOVASCULAR BENEFIT OF EVOLOCUMAB IN 27,564 PATIENTS WITH AND WITHOUT AUTOIMMUNE OR INFLAMMATORY DISEASES: AN ANALYSIS OF THE FOURIER TRIAL
- Author
-
Zimerman, André, Giugliano, Robert P., Kunzler, Ana, Ran, Xinhui, Murphy, Sabina, Wang, Huei, Honarpour, Narimon, and Sabatine, Marc Steven
- Published
- 2024
- Full Text
- View/download PDF
21. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
- Author
-
Anker, Stefan D., Schroeder, Stefan, Atar, Dan, Bax, Jeroen J., Ceconi, Claudio, Cowie, Martin R., Crisp, Adam, Dominjon, Fabienne, Ford, Ian, Ghofrani, Hossein-Ardeschir, Gropper, Savion, Hindricks, Gerhard, Hlatky, Mark A., Holcomb, Richard, Honarpour, Narimon, Jukema, Wouter J., Kim, Albert M., Kunz, Michael, Lefkowitz, Martin, Le Floch, Chantal, Landmesser, Ulf, McDonagh, Theresa A., McMurray, John J., Merkely, Bela, Packer, Milton, Prasad, Krishna, Revkin, James, Rosano, Giuseppe M.C., Somaratne, Ransi, Stough, Wendy Gattis, Voors, Adriaan A., and Ruschitzka, Frank
- Published
- 2016
- Full Text
- View/download PDF
22. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- Author
-
Sabatine, Marc S., Giugliano, Robert P., Keech, Anthony, Honarpour, Narimon, Wang, Huei, Liu, Thomas, Wasserman, Scott M., Scott, Robert, Sever, Peter S., and Pedersen, Terje R.
- Published
- 2016
- Full Text
- View/download PDF
23. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure ( COSMIC ‐ HF )
- Author
-
Biering‐Sørensen, Tor, primary, Minamisawa, Masatoshi, additional, Liu, Jiankang, additional, Claggett, Brian, additional, Papolos, Alexander I., additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Legg, Jason C., additional, Malik, Fady I., additional, Honarpour, Narimon, additional, Kurtz, Christopher E., additional, Teerlink, John R., additional, and Solomon, Scott D., additional
- Published
- 2021
- Full Text
- View/download PDF
24. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)
- Author
-
Biering-Sørensen, Tor, Minamisawa, Masatoshi, Liu, Jiankang, Claggett, Brian, Papolos, Alexander I., Felker, G. Michael, McMurray, John J.V., Legg, Jason C., Malik, Fady I., Honarpour, Narimon, Kurtz, Christopher E., Teerlink, John R., Solomon, Scott D., Biering-Sørensen, Tor, Minamisawa, Masatoshi, Liu, Jiankang, Claggett, Brian, Papolos, Alexander I., Felker, G. Michael, McMurray, John J.V., Legg, Jason C., Malik, Fady I., Honarpour, Narimon, Kurtz, Christopher E., Teerlink, John R., and Solomon, Scott D.
- Published
- 2021
25. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
- Author
-
Teerlink, John R., Diaz, Rafael, Michael Felker, G., McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sorensen, Tor, Bohm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalan, Ramon, Crespo-Leiro, Maria G., Dahlstrom, Ulf, Echeverria, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Candida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin'ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A., Malik, Fady I., Kurtz, Christopher E., Teerlink, John R., Diaz, Rafael, Michael Felker, G., McMurray, John J.V., Metra, Marco, Solomon, Scott D., Adams, Kirkwood F., Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sorensen, Tor, Bohm, Michael, Bonderman, Diana, Cleland, John G.F., Corbalan, Ramon, Crespo-Leiro, Maria G., Dahlstrom, Ulf, Echeverria, Luis E., Fang, James C., Filippatos, Gerasimos, Fonseca, Candida, Goncalvesova, Eva, Goudev, Assen R., Howlett, Jonathan G., Lanfear, David E., Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin'ichi, O'Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A., Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M., Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A., Yilmaz, Mehmet B., Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C., Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A., Malik, Fady I., and Kurtz, Christopher E.
- Abstract
BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.).
- Published
- 2021
26. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- Author
-
Deedwania, Prakash, primary, Murphy, Sabina A., additional, Scheen, Andre, additional, Badariene, Jolita, additional, Pineda, Armando Lira, additional, Honarpour, Narimon, additional, Keech, Anthony C., additional, Sever, Peter S., additional, Pedersen, Terje R., additional, Sabatine, Marc S., additional, and Giugliano, Robert P., additional
- Published
- 2021
- Full Text
- View/download PDF
27. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF
- Author
-
Teerlink, John R, Diaz, Rafael, Felker, G Michael, Mcmurray, John J V, Metra, Marco, Solomon, Scott D, Legg, Jason C, Büchele, Gustavo, Varin, Claire, Kurtz, Christopher E, Malik, Fady I, and Honarpour, Narimon
- Subjects
cardiovascular outcomes trial ,omecamtiv mecarbil ,heart failure ,inotrope ,cardiac myosin activator - Published
- 2020
28. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
- Author
-
Teerlink, John R., primary, Diaz, Rafael, additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Metra, Marco, additional, Solomon, Scott D., additional, Adams, Kirkwood F., additional, Anand, Inder, additional, Arias-Mendoza, Alexandra, additional, Biering-Sørensen, Tor, additional, Böhm, Michael, additional, Bonderman, Diana, additional, Cleland, John G.F., additional, Corbalan, Ramon, additional, Crespo-Leiro, Maria G., additional, Dahlström, Ulf, additional, Echeverria, Luis E., additional, Fang, James C., additional, Filippatos, Gerasimos, additional, Fonseca, Cândida, additional, Goncalvesova, Eva, additional, Goudev, Assen R., additional, Howlett, Jonathan G., additional, Lanfear, David E., additional, Li, Jing, additional, Lund, Mayanna, additional, Macdonald, Peter, additional, Mareev, Viacheslav, additional, Momomura, Shin-ichi, additional, O’Meara, Eileen, additional, Parkhomenko, Alexander, additional, Ponikowski, Piotr, additional, Ramires, Felix J.A., additional, Serpytis, Pranas, additional, Sliwa, Karen, additional, Spinar, Jindrich, additional, Suter, Thomas M., additional, Tomcsanyi, Janos, additional, Vandekerckhove, Hans, additional, Vinereanu, Dragos, additional, Voors, Adriaan A., additional, Yilmaz, Mehmet B., additional, Zannad, Faiez, additional, Sharpsten, Lucie, additional, Legg, Jason C., additional, Varin, Claire, additional, Honarpour, Narimon, additional, Abbasi, Siddique A., additional, Malik, Fady I., additional, and Kurtz, Christopher E., additional
- Published
- 2021
- Full Text
- View/download PDF
29. Loss of Apaf-1 leads to partial rescue of the HAND2-null phenotype
- Author
-
Aiyer, Aparna R., Honarpour, Narimon, Herz, Joachim, and Srivastava, Deepak
- Subjects
Apoptosis -- Research ,Biological sciences - Abstract
HAND2 is an essential transcription factor for cardiac, pharyngeal arch, and limb development. Apoptosis in the HAND2-null embryo causes hypoplasia of the right ventricle and pharyngeal arches leading to lethality by embryonic day (E)10.0 from heart failure. In order to investigate the role of apoptosis in inducing the HAND2-null phenotype, we generated mouse embryos lacking both HAND2 and Apaf-1, a central downstream mediator of mitochondrial damage-induced apoptosis. In contrast to HAND[2.sup.-/-] embryos, HAND[2.sup./-] [Apaf-1.sup.-/-] embryos at E10.5-11.0 had well-developed pharyngeal arches, aortic arch arteries, and no signs of cardiac failure. TUNEL analysis through pharyngeal arches of [HAND2.sup.-/-] [Apaf-1.sup.-/-] embryos revealed decreased apoptosis and the embryos had clearly patent aortic arch arteries. However, ventricular hypoplasia and cell death were unchanged in these animals compared to [HAND2.sup.-/-] embryos, resulting in growth arrest at E11.0. Our study suggests that loss of HAND2 in the pharyngeal arch mesenchyme leads to apoptosis in an Apaf-1-dependent fashion and that, while loss of aortic arch integrity contributes to the early lethality, the ventricular defects are independent of arch development. Keywords: Apaf-1; HAND2-null phenotype; Pharyngeal arches
- Published
- 2005
30. Chapter 24 - Quantitative Microsphere System Omecamtiv Mecarbil Immunoassay and Omecamtiv Mecarbil Codevelopment
- Author
-
Go, Ning Fei, Honarpour, Narimon, and Rigl, Ted
- Published
- 2019
- Full Text
- View/download PDF
31. The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)
- Author
-
Biering-Sørensen, Tor, primary, Papolos, Alexander, additional, Teerlink, John R., additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Legg, Jason C., additional, Malik, Fady I., additional, Honarpour, Narimon, additional, Kurtz, Christopher E., additional, and Solomon, Scott D., additional
- Published
- 2020
- Full Text
- View/download PDF
32. Real‐World Analysis of Guideline‐Based Therapy After Hospitalization for Heart Failure
- Author
-
Wirtz, Heidi S., primary, Sheer, Richard, additional, Honarpour, Narimon, additional, Casebeer, Adrianne W., additional, Simmons, Jeff D., additional, Kurtz, Christopher E., additional, Pasquale, Margaret K., additional, and Globe, Gary, additional
- Published
- 2020
- Full Text
- View/download PDF
33. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
- Author
-
Gencer, Baris, primary, Mach, François, additional, Murphy, Sabina A., additional, De Ferrari, Gaetano M., additional, Huber, Kurt, additional, Lewis, Basil S., additional, Ferreira, Jorge, additional, Kurtz, Christopher E., additional, Wang, Huei, additional, Honarpour, Narimon, additional, Keech, Anthony C., additional, Sever, Peter S., additional, Pedersen, Terje R., additional, Sabatine, Marc S., additional, and Giugliano, Robert P., additional
- Published
- 2020
- Full Text
- View/download PDF
34. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
- Author
-
Wiviott, Stephen D., primary, Giugliano, Robert P., additional, Morrow, David A., additional, De Ferrari, Gaetano M., additional, Lewis, Basil S., additional, Huber, Kurt, additional, Kuder, Julia F., additional, Murphy, Sabina A., additional, Forni, Danielle M., additional, Kurtz, Christopher E., additional, Honarpour, Narimon, additional, Keech, Anthony C., additional, Sever, Peter S., additional, Pedersen, Terje R., additional, and Sabatine, Marc S., additional
- Published
- 2020
- Full Text
- View/download PDF
35. THE EFFECT OF THE CARDIAC MYOSIN ACTIVATOR, MECAMTIV MECARBIL, ON RIGHT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC SYSTOLIC HEART FAILURE (COSMIC-HF)
- Author
-
Biering-Sorensen, Tor, primary, Papolos, Alexander, additional, Teerlink, John, additional, Felker, G. Michael, additional, McMurray, John, additional, Legg, Jason, additional, Malik, Fady, additional, Honarpour, Narimon, additional, Kurtz, Christopher, additional, and Solomon, Scott D., additional
- Published
- 2020
- Full Text
- View/download PDF
36. Adult Apaf-1-Deficient Mice Exhibit Male Infertility
- Author
-
Honarpour, Narimon, Du, Chunying, Richardson, James A., Hammer, Robert E., Wang, Xiaodong, and Herz, Joachim
- Subjects
Developmental biology -- Research ,Infertility, Male -- Research ,Cell death -- Research ,Biological sciences - Abstract
Release of cytochrome c from the mitochondria, and subsequent binding to apoptotic protease-activating factor-1 (Apaf-1), is a key trigger of apoptotic events. A complex composed of Apaf-1, dATP, and cytochrome c activates a series of cytoplasmic proteases called caspases, leading to apoptotic cell death. We have disrupted the Apaf-1 gene in the mouse. Like previous reports on this knockout model, we find that most Apaf-1 mutants die perinatally and frequently exhibit exencephaly and cranioschesis. We additionally find that the neural lesions that develop in the knockout are due to an excess of neural progenitor cells that manifests as early as embryonic day 9.5 in development. In contrast to previous reports on the Apaf-1 knockout mice, we find that 5% of the mutants successfully survive to adulthood. In these survivors, the brain develops normally, but in males, there is degeneration of spermatogonia resulting in the virtual absence of sperm. Thus, cytochrome c-mediated apoptosis is not absolutely required for normal neural development, but is essential for spermatogenesis. These findings strongly suggest that alternative apoptotic pathways work in conjunction with and parallel to Apaf-1 and can modify its effect on programmed cell death.
- Published
- 2000
37. Association between systolic ejection time and outcomes in heart failure by ejection fraction
- Author
-
Patel, Priyesh A., primary, Ambrosy, Andrew P., additional, Phelan, Matthew, additional, Alenezi, Fawaz, additional, Chiswell, Karen, additional, Van Dyke, Melissa K., additional, Tomfohr, Jennifer, additional, Honarpour, Narimon, additional, and Velazquez, Eric J., additional
- Published
- 2019
- Full Text
- View/download PDF
38. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
- Author
-
Murphy, Sabina A., primary, Pedersen, Terje R., additional, Gaciong, Zbigniew A., additional, Ceska, Richard, additional, Ezhov, Marat V., additional, Connolly, Derek L., additional, Jukema, J. Wouter, additional, Toth, Kalman, additional, Tikkanen, Matti J., additional, Im, Kyungah, additional, Wiviott, Stephen D., additional, Kurtz, Christopher E., additional, Honarpour, Narimon, additional, Giugliano, Robert P., additional, Keech, Anthony C., additional, Sever, Peter S., additional, and Sabatine, Marc S., additional
- Published
- 2019
- Full Text
- View/download PDF
39. RS13. Risk of Major Adverse Limb Events and Benefits of Evolocumab in Patients With Peripheral Artery Disease by History of Prior Peripheral Revascularization
- Author
-
Nault, Patrice, primary, Bonaca, Marc, additional, Giugliano, Robert P., additional, Honarpour, Narimon, additional, Keech, Anthony C., additional, Sever, Peter S., additional, Pedersen, Terje R., additional, and Sabatine, Marc, additional
- Published
- 2019
- Full Text
- View/download PDF
40. EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF
- Author
-
Teerlink, John R., primary, Felker, G. Michael, additional, McMurray, John, additional, Solomon, Scott, additional, Cleland, John, additional, Goldsmith, Steven, additional, Kurtz, Christopher, additional, Buchele, Gustavo, additional, Legg, Jason, additional, Malik, Fady, additional, and Honarpour, Narimon, additional
- Published
- 2019
- Full Text
- View/download PDF
41. Evolocumab and clinical outcomes in patients with cardiovascular disease
- Author
-
Sabatine, Marc S., Giugliano, Robert P., Keech, Anthony C., Honarpour, Narimon, Wiviott, Stephen D., Murphy, Sabina A., Kuder, Julia F., Wang, Huei, Liu, Thomas, Wasserman, Scott M., Sever, Peter S., Pedersen, Fish MP, Terje R., Abrahamsen, Te, Im, K, Kanevsky, E, Bonaca, Mp, Lira Pineda, A, Hanlon, K, Knusel, B, Somaratne, R, Kurtz, C, Scott, R, Accini Mendoza JL, Amerena, J, Badariene, J, Burgess, L, Ceska, R, Charng, Mj, Choi, D, Cobos, Jl, Dan, Ga, De Ferrari GM, Deedwania, Pc, Chopra, Vk, Erglis, A, Ezhov, Mv, Ferreira, J, Filipová, S, Gaciong, Za, Pasierski, T, Georgiev, Bg, Gonzalez-Galvez, G, Gouni-Berthold, I, Schäufele, T, Hirayama, A, Huber, K, Rammer, M, Kjaerulf Jensen, H, Wermuth, S, Jiang, L, Jukema, Jw, Kraydashenko, O, Leiter, La, Lewis, Bs, López-Miranda, J, Lorenzatti, Aj, Mach, F, Mcadam, B, Nilsson, L, Olsson, Å, Rallidis, L, Rogelio, Gg, Kerr Saraiva JF, Scheen, A, Schiele, F, Scott, Rs, Connolly, D, Siu, Cw, Tay, L, Thorgeirsson, G, Tikkanen, Mj, Tokgozoglu, Sl, Toth, K, Viigimaa, M, Wan Ahmad WA, Hennekens, Ch, Andreotti, F, Baigent, C, Brown, Wv, Davis, Br, Newcomer, Jw, Wood, Sk, Larosa, J, Ansell, B, Olsson, A, Lowe, C, Zahn, L, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, Singhal, A, Vita, J, Mackinnon, I, Vogel, Dr, Leon de la Fuente, R, Perna, E, Amuchastegui, M, Pacora, F, Hershson, A, Blumberg, E, Glenny, Ja, Colombo, H, Cuadrado, Ja, Nicolosi, L, Rojas, Cg, Ulla, Mr, Hasbani, Eg, Cuneo, C, Lopez Santi RG, Sanabria, Hd, Hrabar, A, Lozada, A, Begg, A, Lehman, S, Wittert, G, Juergens, C, Kostner, K, Beltrame, J, Simpson, R, Sinhal, A, Adams, M, Kritharides, L, Roberts Thomson, P, Cross, D, Thompson, P, Van Gaal, W, Cox, N, Farshid, A, Hammett, C, Garrahy, P, Prasan, A, Horrigan, M, Ebenbichler, C, Hanusch, U, Prager, R, Schernthaner, G, Luger, A, Siostrzonek, P, Toplak, H, Bergler-Klein, J, Paulweber, B, Sinzinger, H, Buysschaert, I, Thoeng, J, Vandekerckhove, H, Catez, E, Verheye, S, Descamps, O, Hoffer, E, Wollaert, B, Chenu, P, van de Borne, P, De Meulemeester, M, Friart, A, Charlier, F, De Raedt, H, Rietzschel, E, Roelandt, R, Lalmand, J, Tavares Russo LA, Reis, G, Duarte Barbosa EC, Vidotti, Mh, Fernandes Manenti ER, Dutra, O, Leaes, Pe, Rech, Rl, Bertolim Precoma, D, Nicolau, Jc, Amoedo, R, Eliaschewitz, Fg, Pereira, A, Kurtz Lisboa HR, Soares Piegas, L, Cunha Borges JL, Ferreira Rossi PR, Pimentel Filho, P, Bodanese, Lc, de Sa Cunha, R, Moura Jorge JC, Ardito, Wr, Barroso de Souza WK, Hissa, M, Izar, Mc, Manolova, A, Kitova, L, Kinova, E, Tzekova, M, Velchev, V, Tarnovska-Kadreva, R, Gotchev, D, Petrov, I, Raev, D, Trendafilova-Lazarova, D, Yotov, Y, Lazov, P, Rahimi, S, St Amour, E, Constance, C, Pesant, Y, Hess, A, Anderson, T, Sussex, B, Henein, S, Tsoukas, G, Pandey, As, Bergeron, J, Hart, R, Gosselin, G, Chehayeb, R, Hamet, P, Hartleib, M, Mukherjee, A, Halperin, F, Petrella, R, Bhargava, R, Lonn, E, Sabbah, E, Bata, I, Cha, J, Gaudet, D, Chapman, K, Murthy, D, Nigro, F, Rupka, D, Gossard, D, Gupta, M, Dowell, A, Mansour, S, Baass, A, Geadah, C, Huynh, T, Peterson, S, Poirier, P, Sabe-Affaki, G, Vertes, G, Crowley, D, Duchesne, L, Pincetti Jofre CP, Potthoff Cardenas, S, Conejeros Kindel, C, Saavedra Gajardo VA, Lanas Zanetti, F, Sepulveda Varela PA, Stockins Fernandez BA, Li, W, Li, D, Zhao, S, Li, Z, Wang, J, Yang, Y, Zhang, L, Yang, P, Zhang, X, Huang, H, Xue, L, Zheng, Z, Huang, W, Dai, H, Su, H, Zeng, X, Zheng, Y, Tang, Y, Yao, Z, Sun, Y, Du, Y, Ge, Z, Yan, J, Chen, X, Liu, F, Pei, H, Yang, X, Cui, H, Gu, Y, Yang, Z, Li, J, Lian, Y, Cui, Y, Wang, D, Jiang, J, Li, X, Chen, J, Mo, Z, Xu, P, He, Y, Zhou, C, Qu, P, Zhu, Y, Liu, Y, Shen, X, Gao, X, Terront Lozano MA, Moncada Corredor MA, Hernandez Triana, E, Botero Lopez, R, Coronel Arroyo JA, Quintero Baiz AE, Sanchez Vallejo, G, Arana Londoño, C, Molina de Salazar DI, Castellanos Bueno, R, Manzur Jattin, F, Cure Cure CA, Sotomayor Herazo, A, Spinar, J, Hala, T, Machkova, M, Klimsa, Z, Polasek, R, Jerabek, O, Kazdera, P, Pozdisek, Z, Vaclavik, J, Frana, P, Elbl, L, Kucera, D, Kryza, R, Malecha, J, Reichert, P, Sochor, K, Ludka, O, Kellnerova, I, Peterka, K, Zidkova, E, Cech, V, Brabec, T, Fiserova, N, Kvasnicka, J, Rosolova, H, Nemecek, E, Adamkova, V, Dunaj, M, Pojsl, S, Cepelak, M, Podpera, I, Kuchar, L, Rysava, D, Burianova, H, Spinarova, L, Skrobakova, J, Charvat, J, Homza, M, Zemanek, J, Koleckar, P, Karen, I, Krupicka, J, Blaha, V, Matuska, J, Brotanek, J, Cifkova, R, Kuchar, R, Vomacka, Z, Kosek, Z, Hulinsky, V, Krejcova, H, Kuchar, J, Jelinek, Z, Jelinek, P, Markdanner Lindgren, L, Saetre Lihn, A, Korsgaard Thomsen, K, Bronnum-Schou, J, Nielsen, H, Nielsen, T, Egstrup, K, Klausen, Ic, Mickley, H, Hove, J, Jeppesen, J, Melchior, T, Schmidt, Eb, Valter, I, Rosenthal, A, Kaik, J, Kork, A, Alt, I, Strand, J, Nieminen, S, Kahri, J, Suomi, J, Nyman, K, Strandberg, Te, Piippo, T, Savolainen, M, Vikman, S, Pucheu, Y, Cariou, B, Henry, P, Ferrari, E, Montalescot, G, Ferrieres, J, Roubille, F, Bonnet, B, Angoulvant, D, Range, G, Bammert, A, Delarche, N, Mariat, C, Cayla, G, Durlach, V, Coisne, D, Paillard, F, Rouzier, R, Goralski, M, Khanoyan, P, Cottin, Y, Ziegler, O, Khalife, K, Le Corvoisier, P, Motreff, P, Spaulding, C, Vanbelle, E, Bourhaial, H, Opitz, C, Kahrmann, G, Contzen, C, Appel, K, Schenkenberger, I, Rinke, A, Trenk, D, Maus, O, Karakas, M, Hanefeld, M, Darius, H, Hetzel, G, Münzel, T, Wöhrle, J, Stawowy, P, Marten, I, Isermann, B, Kast, P, Vorpahl, M, Bosiljanoff, P, Hengstenberg, C, Kassner, U, Salbach, P, Fischer, M, Steiner, S, Wagner, S, Kraatz, U, von Hodenberg, E, Weyland, K, Mantas, I, Tziakas, D, Bousboulas, S, Patsilinakos, S, Mertzanos, G, Panagoulis, C, Bilianou, H, Skoumas, I, Elisaf, M, Manolis, A, Moschos, N, Kochiadakis, G, Ntaios, G, Richter, D, Athyros, V, Kolovou, G, Danias, P, Melidonis, A, Fan, Kyy, Siu, Sc, Hornyik, A, Lakatos, F, Zilahi, Z, Nagy, K, Laszlo, Z, Peterfai, E, Lupkovics, G, Andreka, P, Merkely, B, Herczeg, B, Piros, Ga, Salamon, C, Mark, L, Papp, A, Szakal, I, Edes, I, Mohacsi, A, Tomcsanyi, J, Hajko, E, Nagy, A, Papp, E, Kiss, R, Karadi, I, Sigurdsson, A, Jain, A, Pai, R, Kothiwale, V, Kulkarni, G, Mahajan, A, Aggarwal, S, Mehta, V, Rajadhyaksha, G, Joshi, A, Khandait, V, Parmar, M, Tyagi, S, Airody Govinda, R, Dwivedi, Sk, Parikh, K, Pothineni, Rb, Solanki, B, O’Donnell, M, Crean, P, Barton, J, Shechter, M, Shotan, A, Klutstein, M, Chorin, E, Gavish, D, Kracoff, O, Atar, S, Rigler, S, Hasin, Y, Schiff, E, Merlini, P, Rapezzi, C, Pirro, M, Gonnelli, S, Floresta, Am, Mennuni, M, Ardissino, D, Senni, M, Marenzi, G, Marcucci, R, Sampietro, T, Cosmi, F, Perrone Filardi, P, De Caterina, R, Fedele, Francesco, Moretti, L, Biasucci, Lm, Ferri, C, Go, Y, Kiyosue, A, Higashi, Y, Tokunaga, T, Kawasaki, T, Sakagami, S, Namba, S, Saku, K, Oku, K, Arakawa, T, Iida, H, Nakamura, Y, Yamamoto, K, Hata, Y, Katsuda, Y, Koga, Y, Shimizu, M, Uehara, H, Kajiyama, S, Okamoto, H, Shinozaki, T, Fujino, Y, Funazaki, T, Higa, N, Kaigawa, K, Koike, A, Nakane, H, Sato, K, Satoh, Y, Shirasawa, K, Sugino, H, Tanabe, J, Uemura, O, Yoshimichi, G, Akai, A, Himeno, H, Inage, T, Inoko, M, Kadokami, T, Noguchi, Y, Yamashita, K, Yasumura, Y, Yuge, M, Hosokawa, S, Kawamitsu, K, Kozuma, K, Matsuo, H, Nakashima, E, Okada, M, Wada, A, Yokoya, K, Iwade, K, Kawabata, K, Tanno, H, Ako, J, Fujita, H, Izumiya, Y, Kanno, M, Nunohiro, T, Ohmura, H, Ueno, T, Kakurina, N, Jasinkevica, I, Stukena, I, Veze, I, Eglite, R, Teterovska, D, Sime, I, Strazdiene, V, Venceviciene, L, Gustiene, O, Radzeviciene-Jurgute, R, Kucinskiene, A, Maskon, O, Lee, Cy, Erng, T, Gan, Hw, Mohamed Yusof AK, Ramanathan, Gl, Liew, H, Lopez Alvarado, A, Nevarez Ruiz LA, De los Rios Ibarra MO, Bazzoni Ruiz AE, Ramos Lopez GA, Llamas Esperon GA, De la Peña Topete GDJ, Violante Ortiz RM, Illescas Diaz JJ, Leon Gonzalez, S, Sanchez Diaz CJ, Mendez Machado GF, Venegas Carrillo LA, Aldrete Velasco JA, Cardona Muñoz EG, Leiva Pons JL, Perez Alva JC, van der Zwaan, C, Oomen, A, van de Wal, R, Magro, M, Boswijk, D, Janus, C, Groutars, R, Tonino, W, Cornel, Jh, Oude Ophuis, A, Troquay, R, Liem, A, Westendorp, I, Van Hessen, M, Lok, D, De Nooijer, C, Den Hartog, F, Van Beek, E, Bendermacher, P, Jansen, R, Römer, T, Rensing, B, Hersbach, F, Herrman, J, Ladyjanskaia, G, Karalis, I, Linssen, G, Bokern, M, Visman, A, Kooij, A, Monajemi, H, Lieverse, A, Baker, J, Tie, S, Risberg, K, Hysing, J, Pedersen, T, Hoivik, Ho, Norheim, P, Solnor, L, Hovland, A, Kjaernli, T, Jocson, G, Coching, Rm, Batalla, E, Go, A, Habaluyas, R, Barcinas, R, Sy, Ra, Estepar, Ra, Germar, A, Trebacz, J, Szymkowiak, K, Wnetrzak-Michalska, R, Kopaczewski, J, Przekwas-Jaruchowska, M, Kania, G, Zabowka, M, Mirek-Bryniarska, E, Dabrowska, M, Napora, P, Konieczny, M, Spyra, J, Lysek, R, Pijanowski, Z, Grzegorzewski, B, Bednarkiewicz, Z, Kinasz, L, Antkowiak-Piatyszek, K, Stania, K, Szpajer, M, Staneta, P, Skonieczny, G, Ksiezycka-Majczynska, E, Blicharski, T, Piepiorka, M, Wozakowska-Kaplon, B, Zechowicz, T, Ilkowski, J, Lubiszewska, B, Hiczkiewicz, J, Wierzbicka, K, Kosior, D, Garbocz, P, Kubica, J, Raczak, G, Wozniak, I, Cygler, J, Kramarczuk, E, Bystryk, L, Pentela-Nowicka, J, Dabrowski, M, Podolec, P, Zieba, B, Mosiewicz, J, Dubaniewicz, W, Banach, M, Tyszecka, G, Lepich, T, Rychlewska-Hanczewska, A, Guzik, T, Monteiro, P, Pereira, H, Oliveira, L, Matos, P, Soares Goncalves, S, Leitao, A, Vasco Salgado, A, Timoteo, At, Pintilei, E, Badila, E, Militaru, C, Tudoran, M, Arsenescu-Georgescu, C, Mitu, F, Zdrenghea, D, Lighezan, D, Teodorescu, I, Popescu, Mi, Coman, I, Vintila, Mm, Vishnevsky, A, Lukyanov, Y, Blokhin, A, Kostenko, V, Shvarts, Y, Markov, V, Motylev, I, Dronov, D, Sherenkov, A, Barbarash, O, Shutemova, E, Bolshakova, O, Kobalava, Z, Voevoda, M, Treshkur, T, Zrazhevskiy, K, Pimenov, L, Solovev, O, Tarasov, N, Arkhipov, M, Freidlin, M, Shalaev, S, Yakhontova, P, Shustov, S, Goloshchekin, B, Panov, A, Bart, B, Bubnova, M, Gordeev, I, Osipova, I, Tereshenko, S, Solovieva, E, Meshkov, A, Zateyshchikov, D, Tan, Jl, Subramaniam, T, Pella, D, Fulop, P, Antalik, L, Dzupina, A, Banikova, A, Sosovec, D, Urgeova, L, Mazur, J, Hranai, M, Banik, M, Vinanska, D, Lennerova, J, Kovar, F, Pastrnakova, E, Uhliar, R, Blasko, P, Gonsorcik, J, Lukacova, J, Oriesek, R, Hatalova, K, du Toit, M, Ebrahim, I, Vawda, G, Lipschitz, S, Blignaut, S, Engelbrecht, J, Coetzer, Tf, Pretorius, M, Urbach, D, Badat, A, Pillay, S, Van Zyl, L, Abelson, M, van der Walt, E, Moodley, R, Jacovides, A, Oosthuysen, Wm, Klug, E, Lottering, H, Kok, J, Saaiman, J, Dawood, S, De Jong DM, Kapp, C, Makotoko, E, Bayat, J, Sarvan, M, Vally, T, Stapelberg, A, Kim, M, Bae, J, Cho, Y, Kim, S, Han, Kh, Her, S, Kim, B, Lee, S, Hong, B, Kim, W, Rha, S, Jeong, M, Shin, Gj, Vida Gutierrez, M, Valdes Chavarri, M, Pinto Sala, X, Gonzalez Juanatey JR, Civeira Murillo, F, Zamorano Gomez JL, Lekuona Goya, I, Iñiguez Romo, A, Cordero Fort, A, Ascaso Gimilio JF, Millan Nuñez-Cortes, J, Lindholm, C, Söderberg, S, Suutari, A, Berglund, S, Mooe, T, Kusiak, D, Bandh, S, Dahlén, G, Olsson, S, Witt, N, Tydén, P, Johansson, P, Cizinsky, S, Falck, G, Pettersson, Si, Rasmanis, G, Östergren, J, Moccetti, T, Beer, Hj, Eberli, F, Krähenbühl, S, Linka, A, Ackermann, D, Michel, P, Yeh, H, Tsai, Cf, Wu, C, Hsia, C, Juang, J, Hsieh, I, Lai, W, Huang, C, Hsieh, Y, Sahin, T, Duzenli, M, Yigit, Z, Demir, M, Yilmaz, Mb, Muderrisoglu, Ih, Kirma, C, Ercan, E, Kayikcioglu, L, Balbay, Y, Lymar, I, Kulynych, O, Prokhorov, O, Karpenko, O, Kraіz, I, Vakaliuk, I, Stanislavchuk, M, Korzh, O, Rudyk, I, Zhurba, S, Svishchenko, Y, Tseluyko, V, Gyrina, O, Reshotko, D, Kopytsya, M, Volkov, V, Myshanych, G, Rebrov, B, Rishko, M, Rudenko, L, Shatylo, V, Parkhomenko, O, Yena, L, Golovchenko, O, Sorokina, I, Malynovsky, Y, Ivan, P, Blagden, M, Dear, H, Mathew, A, Lagocki, S, Kondagunta, V, Ahsan, A, Mckinnon, C, Douglas, F, Thom, S, Fiore, G, Caulfield, M, Lynch, M, Thomas, H, Bain, S, Hall, A, Mcnally, D, Fisher, M, Keeling, P, Al-Bahrani, A, Lip, G, Ellery, A, Purohit, J, Travill, C, Cappuccio, F, Davis, G, Gaunt, R, Adlam, D, Asamoah, N, Jaafar, F, Mccormack, T, Jupp, B, Pye, M, Ainsworth, P, Chauhan, A, Paul, N, Fairlie, H, Fox, C, Muzulu, S, Trevelyan, J, Aggarwal, R, Issa, B, Saravanan, P, Cruickshank, K, Gorog, D, Heller, S, Newby, D, Nicolson, A, Hare, Po, Donnelly, P, Rutherfurd, S, de Belder, M, Finlayson, J, Harvey, J, Hoye, A, Kingston, D, Sarkar, D, Negahban, A, Webster, J, Wyatt, N, Muir, S, Cummings, M, Mackenzie, I, Senior, R, Capps, N, Fotherby, K, Mcintyre, H, Aldegather, J, Dixon, L, Saksena, R, Butler, R, Ramstad, D, Pierpont, B, Levinson, D, Mohammed, A, Haddad, T, Goel, A, Dave, K, Haught, Wh, Desire, A, Hershon, K, Napoli, M, Tami, L, Rothschild, R, Khurana, S, Gupta, D, Cheung, D, Hearne, S, Grubb, S, Miller, A, Baird, I, Marcus, A, Srivastava, S, Forgosh, L, Fritz, R, Mays, M, Bertolet, B, Reddy, J, Khan, M, Nakhle, S, Dill, S, Fishbein, G, Khan, B, Marais, H, Reschak, M, Malone, M, Nadar, V, Whitney, R, Reichman, A, Reyes, H, El Shahawy, M, Rabinowitz, A, Weinstein, D, Farhat, N, Onyema, D, Potu, R, Runquist, L, Barnum, O, Crater, T, Fialkow, J, Shah, A, Thompson, C, Wiseman, A, Doyle, T, Henderson, D, Herzog, W, Schnitzler, R, Carr, K, Davis, M, Nagajothi, N, Olsen, S, Rogers, W, Rubino, J, Singh, I, Tarleton, G, Bhagwat, R, Clardy, D, Jardula, M, Robinson, J, Torres, M, Vijay, N, Farris, N, Lillo, J, Moriarty, P, Recknor, C, Berlacher, P, Christensen, T, Gabra, N, Issa, M, Janik, M, Lawless, A, Molter, D, Stout, E, Brezina, B, Claxton, E, Linsky, R, Poock, J, Remler, R, Roseman, H, Schramm, E, Al-Joundi, T, Amin, J, Hitchcock, J, Isserman, S, Kirstein, J, Rider, J, Shalek, M, Sherman, H, Bernstein, M, Chandra, L, Hatharasinghe, R, Ibrahim, H, Iteld, B, Linzmeyer, K, Seaton, B, Zeig, S, Christofides, E, Dunbar, R, Griffin, S, Kohli, N, Koren, M, Pharr, W, Purdy, D, Spencer, R, Yeoman, G, Banerjee, S, Cheek, Hb, Engel, E, Hamroff, G, Huling, R, Kozlowski, L, Levin, P, Makam, S, Meengs, M, Bhushan, R, Erickson, B, Herman, L, Lo, E, Mcdowell, E, Mcgrew, F, Miller, M, Ord, J, Webel, R, Wilhoit, G, Wise, J, Yang, E, Budoff, M, Collins, J, Dauber, I, Dobkin, L, Focil, A, Gandy, W, Pasquini, J, Ramos, M, Rodriguez, D, Rosenson, R, Sanford, K, Schlau, A, Snyder, B, Stonesifer, L, Tang, A, De Souza, J, Elam, M III, French, J, Guyton, J, Hage Korban, E, Kereiakes, D, King, M, Loh, I, Navarro, J, Simons, R, Tobin, T, Younis, L, Aboufakher, R, Baldari, D, Ballantyne, C, Broughton, R, Eaton, C, Johnston, J, Simon, W, Thomson, S, Vora, K, Youngman, D, Alzohaili, O, Auerbach, E, Brown, C, Burrough, B, Chen, Y, Gilpatrick, M, Landzberg, J, Mitchell, C, Rice, L, Rubenfire, M, Sofley, Cw, Strobl, D, Atassi, K, Davila, W, Diogo, J, Fagan, T, Joffe, I, Krishna, J, Osea, E, Penny, W, Rowe, W, Shapiro, M, Welker, J, Benton, R, Dobratz, D, Fortuin, F, Graham, J, Henry, B, Kusnick, B, Lutskiy, M, Mcrae, A, Saway, W, Scott, J, Shah, M, Weinberg, B, Zarich, S, Acheatel, R, Case, C, Earl, J, Fernandez, S, Giugliano, G, Handelsman, Y, Hermany, P, Holder, S, Kashyap, M, Khan, A, Lader, E, Peniston, J, Raoof, T, Sacco, J, Shore, K, Spriggs, D, Stringam, S, Tahirkheli, N, Delgado, E, Derian, W, Greenwald, J, Harris, M, Jackson, R, Marhefka, G, Mcelveen, W, Mooss, A, Morris, P, Murray, J, Pearlstein, P, Raisinghani, A, Rezkalla, S, Sakhrani, L, Schreibman, D, Shaoulian, E, Steinsapir, J, Yataco, A, De La Cruz, A, Fredrick, M, Goldenberg, E, Lee, D, Mccullum, K, Mclellan, B, Stephens, L, Wilson, S, Alfieri, A, Mandviwala, M, Orourke, D, Samal, A, Schmedtje, J, Waxman, F, Carhart, R, Clements, B, Dyke, C, Ghali, J, Gruberg, L, Hack, T, Jehle, A, Pogue, B, Schooley, C, Shifrin, G., National Institute for Health Research, Amgen Inc, University of Zurich, Sabatine, Marc S, Sabatine, M, Giugliano, R, Keech, A, Honarpour, N, Wiviott, S, Murphy, S, Kuder, J, Wang, H, Liu, T, Wasserman, S, Sever, P, Pedersen, T, Fish, M, Abrahamsen, T, Im, K, Kanevsky, E, Bonaca, M, Lira Pineda, A, Hanlon, K, Knusel, B, Somaratne, R, Kurtz, C, Scott, R, Accini Mendoza, J, Amerena, J, Badariene, J, Burgess, L, Ceska, R, Charng, M, Choi, D, Cobos, J, Dan, G, De Ferrari, G, Deedwania, P, Chopra, V, Erglis, A, Ezhov, M, Ferreira, J, Filipova, S, Gaciong, Z, Pasierski, T, Georgiev, B, Gonzalez-Galvez, G, Gouni-Berthold, I, Schaufele, T, Hirayama, A, Huber, K, Rammer, M, Kjaerulf Jensen, H, Wermuth, S, Jiang, L, Jukema, J, Kraydashenko, O, Leiter, L, Lewis, B, Lopez-Miranda, J, Lorenzatti, A, Mach, F, Mcadam, B, Nilsson, L, Olsson, A, Rallidis, L, Rogelio, G, Kerr Saraiva, J, Scheen, A, Schiele, F, Connolly, D, Siu, C, Tay, L, Thorgeirsson, G, Tikkanen, M, Tokgozoglu, S, Toth, K, Viigimaa, M, Wan Ahmad, W, Hennekens, C, Andreotti, F, Baigent, C, Brown, W, Davis, B, Newcomer, J, Wood, S, Larosa, J, Ansell, B, Lowe, C, Zahn, L, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, Singhal, A, Vita, J, Mackinnon, I, Vogel, D, Leon de la Fuente, R, Perna, E, Amuchastegui, M, Pacora, F, Hershson, A, Blumberg, E, Glenny, J, Colombo, H, Cuadrado, J, Nicolosi, L, Rojas, C, Ulla, M, Hasbani, E, Cuneo, C, Lopez Santi, R, Sanabria, H, Hrabar, A, Lozada, A, Begg, A, Lehman, S, Wittert, G, Juergens, C, Kostner, K, Beltrame, J, Simpson, R, Sinhal, A, Adams, M, Kritharides, L, Roberts Thomson, P, Cross, D, Thompson, P, Van Gaal, W, Cox, N, Farshid, A, Hammett, C, Garrahy, P, Prasan, A, Horrigan, M, Ebenbichler, C, Hanusch, U, Prager, R, Schernthaner, G, Luger, A, Siostrzonek, P, Toplak, H, Bergler-Klein, J, Paulweber, B, Sinzinger, H, Buysschaert, I, Thoeng, J, Vandekerckhove, H, Catez, E, Verheye, S, Descamps, O, Hoffer, E, Wollaert, B, Chenu, P, van de Borne, P, De Meulemeester, M, Friart, A, Charlier, F, De Raedt, H, Rietzschel, E, Roelandt, R, Lalmand, J, Tavares Russo, L, Reis, G, Duarte Barbosa, E, Vidotti, M, Fernandes Manenti, E, Dutra, O, Leaes, P, Rech, R, Bertolim Precoma, D, Nicolau, J, Amoedo, R, Eliaschewitz, F, Pereira, A, Kurtz Lisboa, H, Soares Piegas, L, Cunha Borges, J, Ferreira Rossi, P, Pimentel Filho, P, Bodanese, L, de Sa Cunha, R, Moura Jorge, J, Ardito, W, Barroso de Souza, W, Hissa, M, Izar, M, Manolova, A, Kitova, L, Kinova, E, Tzekova, M, Velchev, V, Tarnovska-Kadreva, R, Gotchev, D, Petrov, I, Raev, D, Trendafilova-Lazarova, D, Yotov, Y, Lazov, P, Rahimi, S, St Amour, E, Constance, C, Pesant, Y, Hess, A, Anderson, T, Sussex, B, Henein, S, Tsoukas, G, Pandey, A, Bergeron, J, Hart, R, Gosselin, G, Chehayeb, R, Hamet, P, Hartleib, M, Mukherjee, A, Halperin, F, Petrella, R, Bhargava, R, Lonn, E, Sabbah, E, Bata, I, Cha, J, Gaudet, D, Chapman, K, Murthy, D, Nigro, F, Rupka, D, Gossard, D, Gupta, M, Dowell, A, Mansour, S, Baass, A, Geadah, C, Huynh, T, Peterson, S, Poirier, P, Sabe-Affaki, G, Vertes, G, Crowley, D, Duchesne, L, Pincetti Jofre, C, Potthoff Cardenas, S, Conejeros Kindel, C, Saavedra Gajardo, V, Lanas Zanetti, F, Sepulveda Varela, P, Stockins Fernandez, B, Li, W, Li, D, Zhao, S, Li, Z, Wang, J, Yang, Y, Zhang, L, Yang, P, Zhang, X, Huang, H, Xue, L, Zheng, Z, Huang, W, Dai, H, Su, H, Zeng, X, Zheng, Y, Tang, Y, Yao, Z, Sun, Y, Du, Y, Ge, Z, Yan, J, Chen, X, Liu, F, Pei, H, Yang, X, Cui, H, Gu, Y, Yang, Z, Li, J, Lian, Y, Cui, Y, Wang, D, Jiang, J, Li, X, Chen, J, Mo, Z, Xu, P, He, Y, Zhou, C, Qu, P, Zhu, Y, Liu, Y, Shen, X, Gao, X, Terront Lozano, M, Moncada Corredor, M, Hernandez Triana, E, Botero Lopez, R, Coronel Arroyo, J, Quintero Baiz, A, Sanchez Vallejo, G, Arana Londono, C, Molina de Salazar, D, Castellanos Bueno, R, Manzur Jattin, F, Cure Cure, C, Sotomayor Herazo, A, Spinar, J, Hala, T, Machkova, M, Klimsa, Z, Polasek, R, Jerabek, O, Kazdera, P, Pozdisek, Z, Vaclavik, J, Frana, P, Elbl, L, Kucera, D, Kryza, R, Malecha, J, Reichert, P, Sochor, K, Ludka, O, Kellnerova, I, Peterka, K, Zidkova, E, Cech, V, Brabec, T, Fiserova, N, Kvasnicka, J, Rosolova, H, Nemecek, E, Adamkova, V, Dunaj, M, Pojsl, S, Cepelak, M, Podpera, I, Kuchar, L, Rysava, D, Burianova, H, Spinarova, L, Skrobakova, J, Charvat, J, Homza, M, Zemanek, J, Koleckar, P, Karen, I, Krupicka, J, Blaha, V, Matuska, J, Brotanek, J, Cifkova, R, Kuchar, R, Vomacka, Z, Kosek, Z, Hulinsky, V, Krejcova, H, Kuchar, J, Jelinek, Z, Jelinek, P, Markdanner Lindgren, L, Saetre Lihn, A, Korsgaard Thomsen, K, Bronnum-Schou, J, Nielsen, H, Nielsen, T, Egstrup, K, Klausen, I, Mickley, H, Hove, J, Jeppesen, J, Melchior, T, Schmidt, E, Valter, I, Rosenthal, A, Kaik, J, Kork, A, Alt, I, Strand, J, Nieminen, S, Kahri, J, Suomi, J, Nyman, K, Strandberg, T, Piippo, T, Savolainen, M, Vikman, S, Pucheu, Y, Cariou, B, Henry, P, Ferrari, E, Montalescot, G, Ferrieres, J, Roubille, F, Bonnet, B, Angoulvant, D, Range, G, Bammert, A, Delarche, N, Mariat, C, Cayla, G, Durlach, V, Coisne, D, Paillard, F, Rouzier, R, Goralski, M, Khanoyan, P, Cottin, Y, Ziegler, O, Khalife, K, Le Corvoisier, P, Motreff, P, Spaulding, C, Vanbelle, E, Bourhaial, H, Opitz, C, Kahrmann, G, Contzen, C, Appel, K, Schenkenberger, I, Rinke, A, Trenk, D, Maus, O, Karakas, M, Hanefeld, M, Darius, H, Hetzel, G, Munzel, T, Wohrle, J, Stawowy, P, Marten, I, Isermann, B, Kast, P, Vorpahl, M, Bosiljanoff, P, Hengstenberg, C, Kassner, U, Salbach, P, Fischer, M, Steiner, S, Wagner, S, Kraatz, U, von Hodenberg, E, Weyland, K, Mantas, I, Tziakas, D, Bousboulas, S, Patsilinakos, S, Mertzanos, G, Panagoulis, C, Bilianou, H, Skoumas, I, Elisaf, M, Manolis, A, Moschos, N, Kochiadakis, G, Ntaios, G, Richter, D, Athyros, V, Kolovou, G, Danias, P, Melidonis, A, Fan, K, Siu, S, Hornyik, A, Lakatos, F, Zilahi, Z, Nagy, K, Laszlo, Z, Peterfai, E, Lupkovics, G, Andreka, P, Merkely, B, Herczeg, B, Piros, G, Salamon, C, Mark, L, Papp, A, Szakal, I, Edes, I, Mohacsi, A, Tomcsanyi, J, Hajko, E, Nagy, A, Papp, E, Kiss, R, Karadi, I, Sigurdsson, A, Jain, A, Pai, R, Kothiwale, V, Kulkarni, G, Mahajan, A, Aggarwal, S, Mehta, V, Rajadhyaksha, G, Joshi, A, Khandait, V, Parmar, M, Tyagi, S, Airody Govinda, R, Dwivedi, S, Parikh, K, Pothineni, R, Solanki, B, O'Donnell, M, Crean, P, Barton, J, Shechter, M, Shotan, A, Klutstein, M, Chorin, E, Gavish, D, Kracoff, O, Atar, S, Rigler, S, Hasin, Y, Schiff, E, Merlini, P, Rapezzi, C, Pirro, M, Gonnelli, S, Floresta, A, Mennuni, M, Ardissino, D, Senni, M, Marenzi, G, Marcucci, R, Sampietro, T, Cosmi, F, Perrone Filardi, P, De Caterina, R, Fedele, F, Moretti, L, Biasucci, L, Ferri, C, Go, Y, Kiyosue, A, Higashi, Y, Tokunaga, T, Kawasaki, T, Sakagami, S, Namba, S, Saku, K, Oku, K, Arakawa, T, Iida, H, Nakamura, Y, Yamamoto, K, Hata, Y, Katsuda, Y, Koga, Y, Shimizu, M, Uehara, H, Kajiyama, S, Okamoto, H, Shinozaki, T, Fujino, Y, Funazaki, T, Higa, N, Kaigawa, K, Koike, A, Nakane, H, Sato, K, Satoh, Y, Shirasawa, K, Sugino, H, Tanabe, J, Uemura, O, Yoshimichi, G, Akai, A, Himeno, H, Inage, T, Inoko, M, Kadokami, T, Noguchi, Y, Yamashita, K, Yasumura, Y, Yuge, M, Hosokawa, S, Kawamitsu, K, Kozuma, K, Matsuo, H, Nakashima, E, Okada, M, Wada, A, Yokoya, K, Iwade, K, Kawabata, K, Tanno, H, Ako, J, Fujita, H, Izumiya, Y, Kanno, M, Nunohiro, T, Ohmura, H, Ueno, T, Kakurina, N, Jasinkevica, I, Stukena, I, Veze, I, Eglite, R, Teterovska, D, Sime, I, Strazdiene, V, Venceviciene, L, Gustiene, O, Radzeviciene-Jurgute, R, Kucinskiene, A, Maskon, O, Lee, C, Erng, T, Gan, H, Mohamed Yusof, A, Ramanathan, G, Liew, H, Lopez Alvarado, A, Nevarez Ruiz, L, De los Rios Ibarra, M, Bazzoni Ruiz, A, Ramos Lopez, G, Llamas Esperon, G, De la Pena Topete, G, Violante Ortiz, R, Illescas Diaz, J, Leon Gonzalez, S, Sanchez Diaz, C, Mendez Machado, G, Venegas Carrillo, L, Aldrete Velasco, J, Cardona Munoz, E, Leiva Pons, J, Perez Alva, J, van der Zwaan, C, Oomen, A, van de Wal, R, Magro, M, Boswijk, D, Janus, C, Groutars, R, Tonino, W, Cornel, J, Oude Ophuis, A, Troquay, R, Liem, A, Westendorp, I, Van Hessen, M, Lok, D, De Nooijer, C, Den Hartog, F, Van Beek, E, Bendermacher, P, Jansen, R, Romer, T, Rensing, B, Hersbach, F, Herrman, J, Ladyjanskaia, G, Karalis, I, Linssen, G, Bokern, M, Visman, A, Kooij, A, Monajemi, H, Lieverse, A, Baker, J, Tie, S, Risberg, K, Hysing, J, Hoivik, H, Norheim, P, Solnor, L, Hovland, A, Kjaernli, T, Jocson, G, Coching, R, Batalla, E, Go, A, Habaluyas, R, Barcinas, R, Sy, R, Estepar, R, Germar, A, Trebacz, J, Szymkowiak, K, Wnetrzak-Michalska, R, Kopaczewski, J, Przekwas-Jaruchowska, M, Kania, G, Zabowka, M, Mirek-Bryniarska, E, Dabrowska, M, Napora, P, Konieczny, M, Spyra, J, Lysek, R, Pijanowski, Z, Grzegorzewski, B, Bednarkiewicz, Z, Kinasz, L, Antkowiak-Piatyszek, K, Stania, K, Szpajer, M, Staneta, P, Skonieczny, G, Ksiezycka-Majczynska, E, Blicharski, T, Piepiorka, M, Wozakowska-Kaplon, B, Zechowicz, T, Ilkowski, J, Lubiszewska, B, Hiczkiewicz, J, Wierzbicka, K, Kosior, D, Garbocz, P, Kubica, J, Raczak, G, Wozniak, I, Cygler, J, Kramarczuk, E, Bystryk, L, Pentela-Nowicka, J, Dabrowski, M, Podolec, P, Zieba, B, Mosiewicz, J, Dubaniewicz, W, Banach, M, Tyszecka, G, Lepich, T, Rychlewska-Hanczewska, A, Guzik, T, Monteiro, P, Pereira, H, Oliveira, L, Matos, P, Soares Goncalves, S, Leitao, A, Vasco Salgado, A, Timoteo, A, Pintilei, E, Badila, E, Militaru, C, Tudoran, M, Arsenescu-Georgescu, C, Mitu, F, Zdrenghea, D, Lighezan, D, Teodorescu, I, Popescu, M, Coman, I, Vintila, M, Vishnevsky, A, Lukyanov, Y, Blokhin, A, Kostenko, V, Shvarts, Y, Markov, V, Motylev, I, Dronov, D, Sherenkov, A, Barbarash, O, Shutemova, E, Bolshakova, O, Kobalava, Z, Voevoda, M, Treshkur, T, Zrazhevskiy, K, Pimenov, L, Solovev, O, Tarasov, N, Arkhipov, M, Freidlin, M, Shalaev, S, Yakhontova, P, Shustov, S, Goloshchekin, B, Panov, A, Bart, B, Bubnova, M, Gordeev, I, Osipova, I, Tereshenko, S, Solovieva, E, Meshkov, A, Zateyshchikov, D, Tan, J, Subramaniam, T, Pella, D, Fulop, P, Antalik, L, Dzupina, A, Banikova, A, Sosovec, D, Urgeova, L, Mazur, J, Hranai, M, Banik, M, Vinanska, D, Lennerova, J, Kovar, F, Pastrnakova, E, Uhliar, R, Blasko, P, Gonsorcik, J, Lukacova, J, Oriesek, R, Hatalova, K, du Toit, M, Ebrahim, I, Vawda, G, Lipschitz, S, Blignaut, S, Engelbrecht, J, Coetzer, T, Pretorius, M, Urbach, D, Badat, A, Pillay, S, Van Zyl, L, Abelson, M, van der Walt, E, Moodley, R, Jacovides, A, Oosthuysen, W, Klug, E, Lottering, H, Kok, J, Saaiman, J, Dawood, S, De Jong, D, Kapp, C, Makotoko, E, Bayat, J, Sarvan, M, Vally, T, Stapelberg, A, Kim, M, Bae, J, Cho, Y, Kim, S, Han, K, Her, S, Kim, B, Lee, S, Hong, B, Kim, W, Rha, S, Jeong, M, Shin, G, Vida Gutierrez, M, Valdes Chavarri, M, Pinto Sala, X, Gonzalez Juanatey, J, Civeira Murillo, F, Zamorano Gomez, J, Lekuona Goya, I, Iniguez Romo, A, Cordero Fort, A, Ascaso Gimilio, J, Millan Nunez-Cortes, J, Lindholm, C, Soderberg, S, Suutari, A, Berglund, S, Mooe, T, Kusiak, D, Bandh, S, Dahlen, G, Olsson, S, Witt, N, Tyden, P, Johansson, P, Cizinsky, S, Falck, G, Pettersson, S, Rasmanis, G, Ostergren, J, Moccetti, T, Beer, H, Eberli, F, Krahenbuhl, S, Linka, A, Ackermann, D, Michel, P, Yeh, H, Tsai, C, Wu, C, Hsia, C, Juang, J, Hsieh, I, Lai, W, Huang, C, Hsieh, Y, Sahin, T, Duzenli, M, Yigit, Z, Demir, M, Yilmaz, M, Muderrisoglu, I, Kirma, C, Ercan, E, Kayikcioglu, L, Balbay, Y, Lymar, I, Kulynych, O, Prokhorov, O, Karpenko, O, Kraіz, I, Vakaliuk, I, Stanislavchuk, M, Korzh, O, Rudyk, I, Zhurba, S, Svishchenko, Y, Tseluyko, V, Gyrina, O, Reshotko, D, Kopytsya, M, Volkov, V, Myshanych, G, Rebrov, B, Rishko, M, Rudenko, L, Shatylo, V, Parkhomenko, O, Yena, L, Golovchenko, O, Sorokina, I, Malynovsky, Y, Ivan, P, Blagden, M, Dear, H, Mathew, A, Lagocki, S, Kondagunta, V, Ahsan, A, Mckinnon, C, Douglas, F, Thom, S, Fiore, G, Caulfield, M, Lynch, M, Thomas, H, Bain, S, Hall, A, Mcnally, D, Fisher, M, Keeling, P, Al-Bahrani, A, Lip, G, Ellery, A, Purohit, J, Travill, C, Cappuccio, F, Davis, G, Gaunt, R, Adlam, D, Asamoah, N, Jaafar, F, Mccormack, T, Jupp, B, Pye, M, Ainsworth, P, Chauhan, A, Paul, N, Fairlie, H, Fox, C, Muzulu, S, Trevelyan, J, Aggarwal, R, Issa, B, Saravanan, P, Cruickshank, K, Gorog, D, Heller, S, Newby, D, Nicolson, A, Hare, P, Donnelly, P, Rutherfurd, S, de Belder, M, Finlayson, J, Harvey, J, Hoye, A, Kingston, D, Sarkar, D, Negahban, A, Webster, J, Wyatt, N, Muir, S, Cummings, M, Mackenzie, I, Senior, R, Capps, N, Fotherby, K, Mcintyre, H, Aldegather, J, Dixon, L, Saksena, R, Butler, R, Ramstad, D, Pierpont, B, Levinson, D, Mohammed, A, Haddad, T, Goel, A, Dave, K, Haught, W, Desire, A, Hershon, K, Napoli, M, Tami, L, Rothschild, R, Khurana, S, Gupta, D, Cheung, D, Hearne, S, Grubb, S, Miller, A, Baird, I, Marcus, A, Srivastava, S, Forgosh, L, Fritz, R, Mays, M, Bertolet, B, Reddy, J, Khan, M, Nakhle, S, Dill, S, Fishbein, G, Khan, B, Marais, H, Reschak, M, Malone, M, Nadar, V, Whitney, R, Reichman, A, Reyes, H, El Shahawy, M, Rabinowitz, A, Weinstein, D, Farhat, N, Onyema, D, Potu, R, Runquist, L, Barnum, O, Crater, T, Fialkow, J, Shah, A, Thompson, C, Wiseman, A, Doyle, T, Henderson, D, Herzog, W, Schnitzler, R, Carr, K, Davis, M, Nagajothi, N, Olsen, S, Rogers, W, Rubino, J, Singh, I, Tarleton, G, Bhagwat, R, Clardy, D, Jardula, M, Robinson, J, Torres, M, Vijay, N, Farris, N, Lillo, J, Moriarty, P, Recknor, C, Berlacher, P, Christensen, T, Gabra, N, Issa, M, Janik, M, Lawless, A, Molter, D, Stout, E, Brezina, B, Claxton, E, Linsky, R, Poock, J, Remler, R, Roseman, H, Schramm, E, Al-Joundi, T, Amin, J, Hitchcock, J, Isserman, S, Kirstein, J, Rider, J, Shalek, M, Sherman, H, Bernstein, M, Chandra, L, Hatharasinghe, R, Ibrahim, H, Iteld, B, Linzmeyer, K, Seaton, B, Zeig, S, Christofides, E, Dunbar, R, Griffin, S, Kohli, N, Koren, M, Pharr, W, Purdy, D, Spencer, R, Yeoman, G, Banerjee, S, Cheek, H, Engel, E, Hamroff, G, Huling, R, Kozlowski, L, Levin, P, Makam, S, Meengs, M, Bhushan, R, Erickson, B, Herman, L, Lo, E, Mcdowell, E, Mcgrew, F, Miller, M, Ord, J, Webel, R, Wilhoit, G, Wise, J, Yang, E, Budoff, M, Collins, J, Dauber, I, Dobkin, L, Focil, A, Gandy, W, Pasquini, J, Ramos, M, Rodriguez, D, Rosenson, R, Sanford, K, Schlau, A, Snyder, B, Stonesifer, L, Tang, A, De Souza, J, Elam, M, French, J, Guyton, J, Hage Korban, E, Kereiakes, D, King, M, Loh, I, Navarro, J, Simons, R, Tobin, T, Younis, L, Aboufakher, R, Baldari, D, Ballantyne, C, Broughton, R, Eaton, C, Johnston, J, Simon, W, Thomson, S, Vora, K, Youngman, D, Alzohaili, O, Auerbach, E, Brown, C, Burrough, B, Chen, Y, Gilpatrick, M, Landzberg, J, Mitchell, C, Rice, L, Rubenfire, M, Sofley, C, Strobl, D, Atassi, K, Davila, W, Diogo, J, Fagan, T, Joffe, I, Krishna, J, Osea, E, Penny, W, Rowe, W, Shapiro, M, Welker, J, Benton, R, Dobratz, D, Fortuin, F, Graham, J, Henry, B, Kusnick, B, Lutskiy, M, Mcrae, A, Saway, W, Scott, J, Shah, M, Weinberg, B, Zarich, S, Acheatel, R, Case, C, Earl, J, Fernandez, S, Giugliano, G, Handelsman, Y, Hermany, P, Holder, S, Kashyap, M, Khan, A, Lader, E, Peniston, J, Raoof, T, Sacco, J, Shore, K, Spriggs, D, Stringam, S, Tahirkheli, N, Delgado, E, Derian, W, Greenwald, J, Harris, M, Jackson, R, Marhefka, G, Mcelveen, W, Mooss, A, Morris, P, Murray, J, Pearlstein, P, Raisinghani, A, Rezkalla, S, Sakhrani, L, Schreibman, D, Shaoulian, E, Steinsapir, J, Yataco, A, De La Cruz, A, Fredrick, M, Goldenberg, E, Lee, D, Mccullum, K, Mclellan, B, Stephens, L, Wilson, S, Alfieri, A, Mandviwala, M, Orourke, D, Samal, A, Schmedtje, J, Waxman, F, Carhart, R, Clements, B, Dyke, C, Ghali, J, Gruberg, L, Hack, T, Jehle, A, Pogue, B, Schooley, C, and Shifrin, G
- Subjects
Male ,STATIN THERAPY ,2700 General Medicine ,Disease ,Cardiovascular ,PLACEBO-CONTROLLED TRIAL ,Gastroenterology ,0302 clinical medicine ,Anticholesteremic Agent ,Medicine ,Myocardial infarction ,11 Medical and Health Sciences ,ddc:616 ,Incidence ,Antibodies, Monoclonal ,General Medicine ,Cholesterol ,Cardiovascular Diseases ,Monoclonal ,Drug Therapy, Combination ,Proprotein Convertase 9 ,Antibody ,Aged ,Anticholesteremic Agents ,Atherosclerosis ,Cholesterol, LDL ,Double-Blind Method ,Female ,Follow-Up Studies ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Hypercholesterolemia ,Least-Squares Analysis ,Middle Aged ,Medicine (all) ,REDUCING LIPIDS ,Human ,medicine.medical_specialty ,Evinacumab ,Clinical Trials and Supportive Activities ,PCSK9 INHIBITION ,Follow-Up Studie ,LDL ,03 medical and health sciences ,Drug Therapy ,Clinical Research ,LDL-C ,Least-Squares Analysi ,Science & Technology ,Unstable angina ,PCSK9 ,medicine.disease ,chemistry ,Clinical Biochemistry ,030204 cardiovascular system & hematology ,Bococizumab ,FOURIER Steering Committee and Investigators ,Medical and Health Sciences ,chemistry.chemical_compound ,Antibodies monoclonal ,Cardiovascular Disease ,030212 general & internal medicine ,Stroke ,Humanized ,RISK ,biology ,PCSK9 Inhibitors ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Heart Disease ,Atherosclerosi ,6.1 Pharmaceuticals ,Combination ,Cardiology ,Life Sciences & Biomedicine ,Antibodies, Monoclonal, Humanized ,EZETIMIBE ,610 Medicine & health ,Antibodies ,Medicine, General & Internal ,General & Internal Medicine ,Internal medicine ,CORONARY-HEART-DISEASE ,In patient ,Heart Disease - Coronary Heart Disease ,Alirocumab ,Ldl cholesterol ,business.industry ,Evaluation of treatments and therapeutic interventions ,Evolocumab ,Good Health and Well Being ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,biology.protein ,MODERATE ,Hydroxymethylglutaryl-CoA Reductase Inhibitor ,business - Abstract
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. Methods We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. Results At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P
- Published
- 2017
42. Association between systolic ejection time and outcomes in heart failure by ejection fraction.
- Author
-
Patel, Priyesh A., Ambrosy, Andrew P., Phelan, Matthew, Alenezi, Fawaz, Chiswell, Karen, Van Dyke, Melissa K., Tomfohr, Jennifer, Honarpour, Narimon, and Velazquez, Eric J.
- Subjects
HEART failure ,LOGISTIC regression analysis ,AFRICAN Americans - Abstract
Aims: Worsening heart failure (HF) is associated with shorter left ventricular systolic ejection time (SET), but there are limited data describing the relationship between SET and clinical outcomes. Thus, the objective was to describe the association between SET and clinical outcomes in an ambulatory HF population irrespective of ejection fraction (EF).Methods and Results: We identified ambulatory patients with HF with reduced EF (HFrEF) and HF with preserved EF (HFpEF) who had an outpatient transthoracic echocardiogram performed between August 2008 and July 2010 at a tertiary referral centre. Multivariable logistic regression was used to evaluate the association between SET and 1-year outcomes. A total of 545 HF patients (171 HFrEF, 374 HFpEF) met eligibility criteria. Compared with HFpEF, HFrEF patients were younger [median age 60 years (25th-75th percentiles 50-69) vs. 64 years (25th-75th percentiles 53-74], with fewer females (30% vs. 56%) and a similar percentage of African Americans (36% vs. 35%). Median (25th-75th percentiles) EF with HFrEF was 30% (25-35%) and with HFpEF was 54% (48-58%). Median SET was shorter (280 ms vs. 315 ms, P < 0.001), median pre-ejection period was longer (114 ms vs. 89 ms, P < 0.001), and median relaxation time was shorter (78.7 ms vs. 93.3 ms, P < 0.001) among patients with HFrEF vs. HFpEF. Death or HF hospitalization occurred in 26.9% (n = 46) HFrEF and 11.8% (n = 44) HFpEF patients. After adjustment, longer SET was associated with lower odds of the composite of death or HF hospitalization at 1 year among HFrEF but not HFpEF patients.Conclusion: Longer SET is independently associated with improved outcomes among HFrEF patients but not HFpEF patients, supporting a potential role for normalizing SET as a therapeutic strategy with systolic dysfunction. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
43. RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL
- Author
-
Bohula, Erin Ann, primary, Giugliano, Robert, additional, Leiter, Lawrence, additional, Verma, Subodh, additional, Park, Jeong-Gun, additional, Sever, Peter, additional, Pineda, Armando Lira, additional, Honarpour, Narimon, additional, Wang, Huei, additional, Murphy, Sabina, additional, Keech, Anthony, additional, Pedersen, Terje, additional, and Sabatine, Marc, additional
- Published
- 2018
- Full Text
- View/download PDF
44. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- Author
-
Sabatine, Marc S., Leiter, Lawrence A., Wiviott, Stephen D., Giugliano, Robert P., Deedwania, Prakash, De Ferrari, Gaetano M., Murphy, Sabina A., Kuder, Julia F., Gouni-Berthold, Ioanna, Lewis, Basil S., Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S., Leiter, Lawrence A., Wiviott, Stephen D., Giugliano, Robert P., Deedwania, Prakash, De Ferrari, Gaetano M., Murphy, Sabina A., Kuder, Julia F., Gouni-Berthold, Ioanna, Lewis, Basil S., Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S., and Pedersen, Terje R.
- Abstract
Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated the efficacy and safety of evolocumab by diabetes status and the effect of evolocumab on glycaemia and risk of developing diabetes. Methods FOURIER was a randomised trial of evolocumab (140 mg every 2 weeks or 420 mg once per month) versus placebo in 27 564 patients with atherosclerotic disease who were on statin therapy, followed up for a median of 2.2 years. In this prespecified analysis, we investigated the effect of evolocumab on cardiovascular events by diabetes status at baseline, defined on the basis of patient history, clinical events committee review of medical records, or baseline HbA(1c) of 6 u 5% (48 mmol/mol) or greater or fasting plasma glucose (FPG) of 7.0 mmol/L or greater. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina, or coronary revascularisation. The key secondary endpoint was a composite of cardiovascular death, myocardial infarction, or stroke. We also assessed the effect of evolocumab on glycaemia, and on the risk of new-onset diabetes among patients without diabetes at baseline. HbA 1c was measured at baseline then every 24 weeks and FPG was measured at baseline, week 12, week 24, and every 24 weeks thereafter, and potential cases of new-onset diabetes were adjudicated centrally. In a post-hoc analysis, we also investigated the effects on glycaemia and diabetes risk in patients with prediabetes (HbA (c) 5.7-6.4% [39-46 mmol/mol] or FPG 5.6-6.9 mmol/L) at baseline. FOURIER is registered with ClinicalTrials. gov, number NCT01764633. Findings At study baseline, 11 031 patients (40%) had diabetes and 16 533 (60%) did not have diabetes (of whom 10 344 had prediabetes and 6189 had normoglycaemia). Evolocumab significantly reduced cardiovascular out
- Published
- 2017
45. Erratum to 'Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency' [Eur J Heart Fail 2016;18:482-489]
- Author
-
Anker, Stefan D, Schroeder, Stefan, Atar, Dan, Bax, Jeroen J, Ceconi, Claudio, Cowie, Martin R, Crisp, Adam, Dominjon, Fabienne, Ford, Ian, Ghofrani, Hossein-Ardeschir, Gropper, Savion, Hindricks, Gerhard, Hlatky, Mark A, Holcomb, Richard, Honarpour, Narimon, Jukema, J Wouter, Kim, Albert M, Kunz, Michael, Lefkowitz, Martin, Floch, Chantal Le, Landmesser, Ulf, McDonagh, Theresa A, McMurray, John J, Merkely, Bela, Packer, Milton, Prasad, Krishna, Revkin, James, Rosano, Giuseppe M C, Somaratne, Ransi, Stough, Wendy Gattis, et al, and University of Zurich
- Subjects
10209 Clinic for Cardiology ,610 Medicine & health ,Cardiology and Cardiovascular Medicine ,2705 Cardiology and Cardiovascular Medicine - Published
- 2016
46. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
- Author
-
Anker, Stefan D, Schroeder, Stefan, Atar, Dan, Bax, Jeroen J, Ceconi, Claudio, Cowie, Martin R, Crisp, Adam, Dominjon, Fabienne, Ford, Ian, Ghofrani, Hossein-Ardeschir, Gropper, Savion, Hindricks, Gerhard, Hlatky, Mark A, Holcomb, Richard, Honarpour, Narimon, Jukema, J Wouter, Kim, Albert M, Kunz, Michael, Lefkowitz, Martin, Le Floch, Chantal, Landmesser, Ulf, McDonagh, Theresa A, McMurray, John J, Merkely, Bela, Packer, Milton, Prasad, Krishna, Revkin, James, Rosano, Giuseppe M C, Somaratne, Ransi, Stough, Wendy Gattis, et al, University of Zurich, and Anker, Stefan D
- Subjects
10209 Clinic for Cardiology ,610 Medicine & health ,Cardiology and Cardiovascular Medicine ,2705 Cardiology and Cardiovascular Medicine - Published
- 2016
47. Cognitive Function in a Randomized Trial of Evolocumab
- Author
-
Giugliano, Robert P., primary, Mach, François, additional, Zavitz, Kenton, additional, Kurtz, Christopher, additional, Im, Kyungah, additional, Kanevsky, Estella, additional, Schneider, Jingjing, additional, Wang, Huei, additional, Keech, Anthony, additional, Pedersen, Terje R., additional, Sabatine, Marc S., additional, Sever, Peter S., additional, Robinson, Jennifer G., additional, Honarpour, Narimon, additional, Wasserman, Scott M., additional, and Ott, Brian R., additional
- Published
- 2017
- Full Text
- View/download PDF
48. Effect of Omecamtiv Mecarbil in Patients with Ischemic and Non-Ischemic Heart Failure with Reduced Ejection Fraction: Results From COSMIC-HF
- Author
-
Teerlink, John R., primary, Felker, G.M. Ichael, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, Kurtz, Christopher E., additional, Monslavo, Maria Laura, additional, Johnston, James, additional, Malik, Fady I., additional, and Honarpour, Narimon, additional
- Published
- 2017
- Full Text
- View/download PDF
49. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment
- Author
-
Cowie, Martin R., primary, Filippatos, Gerasimos S., additional, Alonso Garcia, Maria de los Angeles, additional, Anker, Stefan D., additional, Baczynska, Anna, additional, Bloomfield, Daniel M., additional, Borentain, Maria, additional, Bruins Slot, Karsten, additional, Cronin, Maureen, additional, Doevendans, Pieter A., additional, El-Gazayerly, Amany, additional, Gimpelewicz, Claudio, additional, Honarpour, Narimon, additional, Janmohamed, Salim, additional, Janssen, Heidi, additional, Kim, Albert M., additional, Lautsch, Dominik, additional, Laws, Ian, additional, Lefkowitz, Martin, additional, Lopez-Sendon, Jose, additional, Lyon, Alexander R., additional, Malik, Fady I., additional, McMurray, John J.V., additional, Metra, Marco, additional, Figueroa Perez, Santiago, additional, Pfeffer, Marc A., additional, Pocock, Stuart J., additional, Ponikowski, Piotr, additional, Prasad, Krishna, additional, Richard-Lordereau, Isabelle, additional, Roessig, Lothar, additional, Rosano, Giuseppe M.C., additional, Sherman, Warren, additional, Stough, Wendy Gattis, additional, Swedberg, Karl, additional, Tyl, Benoit, additional, Zannad, Faiez, additional, Boulton, Caroline, additional, and De Graeff, Pieter, additional
- Published
- 2017
- Full Text
- View/download PDF
50. THE CARDIAC MYOSIN ACTIVATOR, OMECAMTIV MECARBIL, IMPROVES LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN CHRONIC HEART FAILURE (COSMIC-HF)
- Author
-
Biering-Sorensen, Tor, primary, Teerlink, John, additional, Felker, G. Michael, additional, McMurray, John, additional, Malik, Fady, additional, Honarpour, Narimon, additional, Monsalvo, Maria Laura, additional, Johnston, James, additional, and Solomon, Scott D., additional
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.